Universität zu Köln

Hoffmann, Fabian, Fassbender, Patricia, Zander, Wilhelm, Ulbrich, Lisa, Kuhr, Kathrin, Adler, Christoph, Halbach, Marcel and Reuter, Hannes (2022). The Hypertension Paradox: Survival Benefit After ST-Elevation Myocardial Infarction in Patients With History of Hypertension. A Prospective Cohort- and Risk-Analysis. Front. Cardiovasc. Med., 9. LAUSANNE: FRONTIERS MEDIA SA. ISSN 2297-055X

Full text not available from this repository.

Abstract

BackgroundMortality after ST-elevation myocardial infarction (STEMI) is dependent from best-medical treatment after initial event. ObjectivesDetermining the impact of prescription of guideline-recommended therapy after STEMI in two cohorts, patients with and without history of arterial hypertension, on survival. Methods1,025 patients of the Cologne Infarction Model registry with invasively adjudicated STEMI were dichotomized according to their history of arterial hypertension. We recorded prescription rates and dosing of RAS-inhibitors, beta-blockers and statins in all patients. The primary outcome was all-cause death. Mean follow-up was 2.5 years. ResultsMean age was 64 +/- 13 years, 246 (25%) were women. 749 (76%) patients had a history of hypertension. All-cause mortality was 24.2%, 30-day and 1-year mortality was 11.3% and 16.6%, respectively. History of hypertension correlated with lower mortality (hazard ratio [HR], @30 days: 0.41 [0.27-0.62], @1 year: 0.37 [0.26-0.53]). After adjusting for age, sex, Killip-class, diabetes mellitus, body-mass index, kidney function and statin prescription at discharge 1-year mortality HR was 0.24 (0.12-0.48). At discharge, prescription rates for RAS-inhibitors, beta-blockers and statins, as well as individual dosing and long-term persistence of RAS-inhibitors were higher in patients with history of hypertension. On the same lines, prescription rates for RAS-inhibitors, beta-blockers and statins at discharge correlated significantly with lower mortality regardless of history of hypertension. ConclusionPatients with history of hypertension show higher penetration of guideline recommended drug therapy after STEMI, which may contribute to better survival. Better tolerance of beta-blockers and RAS-inhibitors in patients with history of hypertension, not hypertension itself, likely explains these differences in prescription and dosing.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Hoffmann, Fabian UNSPECIFIED UNSPECIFIED UNSPECIFIED Fassbender, Patricia UNSPECIFIED UNSPECIFIED UNSPECIFIED Zander, Wilhelm UNSPECIFIED UNSPECIFIED UNSPECIFIED Ulbrich, Lisa UNSPECIFIED UNSPECIFIED UNSPECIFIED Kuhr, Kathrin UNSPECIFIED UNSPECIFIED UNSPECIFIED Adler, Christoph UNSPECIFIED UNSPECIFIED UNSPECIFIED Halbach, Marcel UNSPECIFIED UNSPECIFIED UNSPECIFIED Reuter, Hannes UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-678943
DOI:	10.3389/fcvm.2022.785657
Journal or Publication Title:	Front. Cardiovasc. Med.
Volume:	9
Date:	2022
Publisher:	FRONTIERS MEDIA SA
Place of Publication:	LAUSANNE
ISSN:	2297-055X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PERCUTANEOUS CORONARY INTERVENTION; CONVERTING ENZYME-INHIBITORS; LEFT-VENTRICULAR DYSFUNCTION; BETA-BLOCKER THERAPY; SEGMENT-ELEVATION; CLINICAL-OUTCOMES; HEART-FAILURE; METAANALYSIS; GUIDELINES; MANAGEMENT Multiple languages Cardiac & Cardiovascular Systems Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/67894